Process for synthesizing keto-benzofuran derivatives

ABSTRACT

The invention relates to a process for synthesizing benzofuran derivatives, in particular dronedarone of formula (D), comprising a step of Friedel-Crafts acylation starting from a sulfonamido-benzofuran ester intermediate.

The present invention relates to keto benzofuran derivatives of generalformula (I) represented below, and also to a process for synthesizingthem via coupling between a quinoneimine and a keto ester, and tosynthetic intermediates thereof.

In the keto benzofuran derivatives of formula (I),

G1 represents a linear or branched alkyl (i), haloalkyl (ii), cycloalkyl(iii), substituted or unsubstituted aryl (iv), alkene (v) or alkyne (vi)group,

G3 represents (i) a group —NHSO₂Rc or (ii) a group —NHRc, in which Rcrepresents (a) a linear or branched alkyl group, (b) a cycloalkyl groupor (c) a substituted or unsubstituted aryl group,

G5 represents a halogen atom or a group —ORb in which Rb represents ahydrogen atom, an alkyl, haloalkyl, aryl, arylalkyl, heteroaryl,cycloalkyl or heterocycloalkyl group or an -alkyleneaminoalkyl group,

Ra is chosen from a hydrogen atom, halogen atoms and alkyl, haloalkyl,alkoxy and alkoxyalkyl groups,

na is an index equal to 0, 1, 2, 3 or 4.

A particularly advantageous derivative of the keto benzofurans (I) is2-n-butyl-3-[4-(3-di-n-butylaminopropoxy)benzoyl]-5-methylsulfonamidobenzofuran,known under the name dronedarone. Dronedarone, of formula (D) below:

may be in the form of the free base or in salt form, in particular thehydrochloride salt of2-n-butyl-3-[4-(3-di-n-butylaminopropoxy)benzoyl]-5-methylsulfonamidobenzofuran.

Dronedarone proves to be particularly useful as an active principle inindications of cardiac arrhythmia.

At the present time, dronedarone in free base form is synthesizedaccording to the process described in EP 0 471 609 B1 via the keyintermediate bearing a benzofuran nucleus, 2-butyl-5-nitrobenzofuran. Inthis synthetic process, the intermediate 2-butyl-5-nitrobenzofuran mustbe:

-   -   a) functionalized in position 3 in several steps involving,        inter alia, a

Friedel-Crafts reaction and then a demethylation, and ending with anO-alkylation

-   -   b) transformed in position 5, according to scheme 1 below. The        nitro group borne in position 5 of 2-butyl-5-nitrobenzofuran        must be converted into methanesulfonamide by a reduction of —NO₂        to —NH₂ followed by a sulfonylation.

The complexity of the technical implementation of this type of processproves to be problematic and prejudicial in terms of yield, safety (useof hydrogen and of alkylating reagent during the mesylation) and of theenvironment (generation of iron or aluminum salts during theFriedel-Crafts step and the demethylation, and release of methyl halidefor the latter step).

The Applicant thus sought novel synthetic routes using benzofurans,preferably already functionalized in positions 2, 3 and 5 of thebenzofuran nucleus and advantageously already suitably functionalized inpositions 2 and 5, in order to perform the synthesis of molecules offormula (I) above, thus making it possible to overcome the technicaldifficulties while at the same time optimally satisfying the cost,toxicity, safety and environmental friendliness constraints associatedwith the industrialization of such a synthetic process.

The Applicant has now found a novel process for synthesizing ketobenzofuran derivatives of formula (I), in particular a novel process forsynthesizing dronedarone of formula (D) above, comprising a step ofFriedel-Crafts acylation or a Fries rearrangement reaction starting witha common intermediate. This process has the advantage of being able tosynthesize the final molecule (I) from a common intermediate via twopossible pathways which are referred to hereinbelow as route A and routeB, affording a certain level of industrial flexibility.

According to a first aspect, the invention is directed toward a processfor synthesizing a keto benzofuran derivative, in acid form (i), in baseform (ii), in the form of an addition salt with an acid or a base (iii),in hydrate form (iv) or in solvate form (v), advantageously dronedaroneor the hydrochloride salt thereof, said keto benzofuran derivative beingof formula (I) below:

in which

G1 represents (i) a linear or branched alkyl group, advantageously aC1-C8 alkyl group and even more advantageously a C1-C4 alkyl group, forinstance a methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl ortert-butyl group, (ii) a haloalkyl group, (iii) a cycloalkyl group, (iv)a substituted or unsubstituted aryl group, (v) an alkene group or (vi)an alkyne group, advantageously G1 represents an alkyl group and evenmore advantageously G1 represents an n-butyl group;

G3 represents (i) a group —NHSO₂Rc or (ii) a group —NHRc, in which Rcrepresents (a) a linear or branched alkyl group, advantageously a C1-C8alkyl group and even more advantageously a C1-C4 alkyl group, forinstance a methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl ortert-butyl group, (b) a cycloalkyl group or (c) a substituted orunsubstituted aryl group, advantageously G3 represents a group—NHSO₂alkyl or a group —NHSO₂aryl, and even more advantageously G3represents a group —NHSO₂CH₃;

G5 represents a halogen atom or a group —ORb in which Rb represents ahydrogen atom, an alkyl, haloalkyl, aryl, arylalkyl, heteroaryl,cycloalkyl or heterocycloalkyl group or an -alkyleneaminoalkyl group,advantageously G5 represents a group —ORb with Rb chosen from-alkyleneaminoalkyl groups, advantageously Rb represents a3-(di-n-butylamino)propyl group;

Ra represents a substituent chosen from a hydrogen atom, halogen atomsand alkyl, haloalkyl, alkoxy and alkoxyalkyl groups, advantageously Rarepresents a substituent chosen from a hydrogen atom, halogen atoms andalkyl groups,

na is an index equal to 0, 1, 2, 3 or 4, said process comprising (i) aFriedel-Crafts acylation reaction or (ii) a Fries rearrangementreaction, said reactions taking place starting with an intermediate offormula (II)

in which the groups G1 and G3 are as defined above and in which thegroup G2 is chosen

-   -   from halogen atoms, the —OH group, alkoxy and aryloxy groups and        —NRdRe with Rd and Re being identical or different and being        chosen, independently of each other, from a hydrogen atom, alkyl        groups and aryl groups, said alkyl and aryl groups being        optionally substituted, advantageously G2 is chosen from halogen        atoms, and even more advantageously G2 is chosen from chlorine        and bromine, in the case where said intermediate (II) is engaged        in a Friedel-Crafts reaction;        or    -   from the following groups

in which the phenyl is optionally substituted in the ortho and/or metaposition, but never in the para position, with said radical Ra, with Raand na as defined above,

-   -   in the case where said intermediate (II) is engaged in a Fries        reaction.

According to one embodiment, the invention is directed toward a processfor synthesizing a keto benzofuran derivative, in base form (i), or inthe form of an addition salt with an acid (ii), advantageouslydronedarone or the hydrochloride salt thereof, said keto benzofuranderivative being of formula (I) below:

in which

G1 represents (i) a linear or branched alkyl group, advantageously aC1-C8 alkyl group and even more advantageously a C1-C4 alkyl group, forinstance a methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl ortert-butyl group, (ii) a haloalkyl group, (iii) a cycloalkyl group, (iv)a substituted or unsubstituted aryl group, (v) an alkene group or (vi)an alkyne group, advantageously G1 represents an alkyl group and evenmore advantageously G1 represents an n-butyl group;

G3 represents (i) a group —NHSO₂Rc or (ii) a group —NHRc, in which Rcrepresents (a) a linear or branched alkyl group, advantageously a C1-C8alkyl group and even more advantageously a C1-C4 alkyl group, forinstance a methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl ortert-butyl group, (b) a cycloalkyl group or (c) a substituted orunsubstituted aryl group, advantageously G3 represents a group—NHSO₂alkyl or a group —NHSO₂aryl, and even more advantageously G3represents a group —NHSO₂CH₃;

G5 represents a halogen atom or a group —ORb in which Rb represents ahydrogen atom, an alkyl, haloalkyl, aryl, arylalkyl, heteroaryl,cycloalkyl or heterocycloalkyl group or an -alkyleneaminoalkyl group,advantageously G5 represents a group —ORb with Rb chosen from a hydrogenatom and -alkyleneaminoalkyl groups, advantageously Rb represents a3-(di-n-butylamino)propyl group;

Ra represents a substituent chosen from halogen atoms and alkyl,haloalkyl, alkoxy and alkoxyalkyl groups, advantageously Ra represents asubstituent chosen from halogen atoms and alkyl groups,

na is an index equal to 0, 1, 2, 3 or 4,

said process comprising a Friedel-Crafts acylation reaction, saidreaction taking place starting with an intermediate of formula (II)

in which the groups G1 and G3 are as defined above and in which thegroup G2 is chosen

-   -   from halogen atoms, the —OH group, alkoxy and aryloxy groups and        —NRdRe with Rd and Re being identical or different and being        chosen, independently of each other, from a hydrogen atom, alkyl        groups and aryl groups, said alkyl and aryl groups being        optionally substituted, advantageously G2 is chosen from halogen        atoms, and even more advantageously G2 is chosen from chlorine        and bromine.

The compounds of formula (I) can comprise one or more asymmetric carbonatoms. They can therefore exist in the form of enantiomers ordiastereoisomers. These enantiomers, diastereoisomers and also mixturesthereof, including racemic mixtures, form part of the invention.

The compounds of formula (I) may exist in the form of bases or ofpharmaceutically acceptable addition salts with organic or mineralacids. Such addition salts form part of the invention. These salts maybe prepared with pharmaceutically acceptable acids, but salts of otheracids that are of use, for example, for purifying or isolating thecompounds of formula (I) also form part of the invention.

According to another aspect, the invention also relates to syntheticintermediates such as the compounds of formulae (II), (VIII) and (IX),in base form, or in the form of pharmaceutically acceptable additionsalts with organic or mineral acids, for example the salts defined abovefor formula (I), said compounds (II), (VIII) and (IX) having thefollowing formula:

in which G1 and G3 are as defined for the keto benzofuran of formula (I)above and in which the group G2 is chosen

-   -   from halogen atoms, the —OH group, alkoxy and aryloxy groups and        —NRdRe with Rd and Re being identical or different and being        chosen, independently of each other, from a hydrogen atom, alkyl        groups and aryl groups, said alkyl and aryl groups being        optionally substituted, advantageously G2 is chosen from halogen        atoms, and even more advantageously G2 is chosen from chlorine        and bromine,        or    -   from the following groups

in which the phenyl is optionally substituted in the ortho and/or metaposition, but never in the para position, with said radical Ra, with Raand na as defined above for the keto benzofuran (I).

According to another aspect, the invention also relates to syntheticintermediates such as the compounds of formula (II), in base form, or inthe form of pharmaceutically acceptable addition salts with organic ormineral acids, said compound (II) having the following formula:

in whichG1 is as defined for the keto benzofuran of formula (I) above;G2 is chosen from halogen atoms, the —OH group, alkoxy and aryloxygroups and —NRdRe with Rd and Re being identical or different and beingchosen, independently of each other, from a hydrogen atom, alkyl groupsand aryl groups, said alkyl and aryl groups being optionallysubstituted;G3 represents (i) a group —NHSO₂Rc or (ii) a group —NHRc, in which Rerepresents (a) a linear or branched alkyl group or (b) a cycloalkylgroup.

According to another aspect, the invention also relates to syntheticintermediates such as the compounds of formula (VIII), in base form, orin the form of pharmaceutically acceptable addition salts with organicor mineral acids, said compound (VIII) having the following formula:

in whichG1 is as defined for the keto benzofuran of formula (I) above;G2 is chosen from halogen atoms, the —OH group, alkoxy and aryloxygroups and —NRdRe with Rd and Re being identical or different and beingchosen, independently of each other, from a hydrogen atom, alkyl groupsand aryl groups, said alkyl and aryl groups being optionallysubstituted;G3 represents (i) a group —NHSO₂Rc or (ii) a group —NHRc, in which Rcrepresents (a) a linear or branched alkyl group, (b) a cycloalkyl groupor (c) a substituted aryl group,

According to another aspect, the invention also relates to syntheticintermediates such as the compounds of formula (IX), in base form, or inthe form of pharmaceutically acceptable addition salts with organic ormineral acids, said compound (IX) having the following formula:

in which G1 and G3 are as defined for the keto benzofuran of formula (I)above and in which the group G2 is chosen from halogen atoms, the —OHgroup, alkoxy and aryloxy groups and —NRdRe with Rd and Re beingidentical or different and being chosen, independently of each other,from a hydrogen atom, alkyl groups and aryl groups, said alkyl and arylgroups being optionally substituted.

According to another aspect, the invention also relates to syntheticintermediates such as the compounds of formula (12), in base form, or inthe form of pharmaceutically acceptable addition salts with organic ormineral acids, said compound having the following formula:

in which

G1, Ra, Rb, Rc and na are as defined for the above keto benzofuran (I),with the exclusion of the compoundN[2-butyl-3-(4-hydroxybenzoyl)benzofuran-5- yl]methanesulfonamide.

According to one embodiment, the invention also relates to syntheticintermediates such as the compounds of formula (12), in base form, or inthe form of pharmaceutically acceptable addition salts with organic ormineral acids, said compound having the following formula:

in which

G1 represents a haloalkyl, cycloalkyl, substituted or unsubstitutedaryl, alkene or alkyne group,

Ra, Rb, Rc and na are as defined for the keto benzofuran (I) above.

In the context of the present invention, and unless otherwise mentionedin the text, the following will be understood:

-   -   the numbering of the positions of the benzofuran nucleus is        performed in the following manner:

-   -   a halogen atom: a fluorine, chlorine, bromine or iodine atom;    -   an alkyl group: a saturated, linear or branched aliphatic group,        which may comprise 1, 2, 3, 4 or 5 carbon atoms (abbreviated as        —(C1-C5)alkyl). Examples that may be mentioned include (i) as        —C1 alkyl group, the methyl group, (ii) as —C2alkyl group, the        ethyl group, (iii) as —C3alkyl group, the n-propyl group and the        isopropyl group, (iv) as —C4alkyl group, the n-butyl group, the        isobutyl group and the tert-butyl group, (v) as —C5alkyl group,        the n-pentyl group and the isopentyl group;    -   a haloalkyl group: an alkyl group as defined above substituted        with 1, 2, 3, 4 or 5 halogen atoms, as defined previously.        Examples that will be mentioned are the -halo(C1-C5)alkyl        groups, with (C1-C5)alkyl as defined above, for instance the        trifluoromethyl group (abbreviated —CF₃) and the —CH₂-CF₃ group;    -   an alkylene group: a saturated, linear or branched, divalent        alkyl group as defined previously, which may comprise 1, 2, 3, 4        or 5 carbon atoms (abbreviated —(C1-C5)alkylene-) or        —(CH₂)_(1 to 5)—. Examples that may be mentioned include        methylene (or —CH₂—), ethylene (or —CH₂-CH₂—) and propylene        (—CH₂-CH₂-OH₂- or —C(CH₃)₂—) radicals;    -   an alkoxy group: a radical —O-alkyl in which the alkyl group is        as defined previously. Examples that may be mentioned include        groups —O—(C1-C5)alkyl or —(C1-C5)alkoxy, and in particular (i)        as group —O—C1alkyl, the group —Omethyl, (ii) as group        ——C2alkyl, the group —Oethyl, (iii) as group —O—C3alkyl, the        group —Opropyl and the group —Oisopropyl, (iv) as group        —O—C4alkyl, the group —Obutyl, the group —Oisobutyl and the        group —Otert-butyl, (v) as group —O—C5alkyl, the group —Opentyl,        the group —Oisopentyl and the group —Oneopentyl;    -   an aryloxy group: a radical —O-aryl in which the aryl group is        as defined below;    -   an aryl group: a cyclic aromatic group comprising 6, 7, 8, 9 or        10 carbon atoms. Examples of aryl groups that may be mentioned        include the phenyl group (abbreviated Ph), the naphthyl group, a        —C₆H₄-alkyl group (with the alkyl radical, as defined        previously, in the ortho, meta or para position on the aromatic        nucleus). —C₆H₄-alkyl groups that may be mentioned include        —C₆H₄-CH₃ groups with CH₃ in the ortho, meta or para position;    -   an arylalkyl group: an aryl group, as defined above, substituted        with at least one alkyl group, as defined above. Advantageously,        they are -alkylaryl radicals. An example that may be mentioned        is the benzyl radical, i.e. the radical —CH₂-Ph;    -   an alkoxyalkyl group: a radical of formula -alkylene-O-alkyl, in        which the alkyl and alkylene groups, comprising the same carbon        number or not comprising the same carbon number, are as defined        previously. Examples that may be mentioned include the groups        —(C1-C5)alkylene-O—(C1-C5)alkyl, with —(C1-C5)alkylene- and        —(C1-C5)alkyl as defined above;    -   an alkoxyaryl group: a radical of formula -alkylene-O-aryl, in        which the aryl and alkylene groups, comprising the same carbon        number or not comprising the same carbon number, are as defined        previously. Examples that may be mentioned include the groups        —(C1-C5)alkylene-O—(C1-C5)alkyl, with —(C1-C5)alkylene- and        —(C1-C5)alkyl as defined above;    -   a heteroaryl group: a cyclic aromatic group comprising 2, 3, 4        or 5 carbon atoms and comprising 1, 2 or 3 heteroatoms, which        may be chosen independently of each other, so as to be identical        or different, when there are 2 of them, or independently of each        other, so as to be identical or different, when there are 3 of        them, from a nitrogen atom, an oxygen atom and a sulfur atom.        Mention may be made of pyridyl, furanyl and pyrrolyl groups;    -   a cycloalkyl group: a cyclic alkyl group, which may comprise 3,        4, 5, or 6 carbon atoms, also abbreviated —(C3-C6)cycloalkyl.        Examples that may be mentioned include cyclopropyl, cyclobutyl,        cyclopentyl and cyclohexyl groups;    -   a heterocycloalkyl: an optionally bridged cyclic alkyl group        comprising 5, 6 or 7 carbon atoms and comprising 1, 2 or 3        heteroatoms, which may be chosen, independently of each other,        so as to be identical or different, when there are 2 of them, or        independently of each other, so as to be identical or different,        when there are 3 of them, from a nitrogen atom, an oxygen atom        and a sulfur atom. Mention may be made especially of piperidyl,        piperazinyl, pyrrolidinyl, hexamethyleneimino, morpholinyl and        1,1-dioxydotetrahydrothienyl groups;    -   an alkyleneaminoalkyl group: a group of formula        -alkylene-N(alkyl)₂, in which the alkylene and alkyl groups,        comprising the same carbon number or not comprising the same        carbon number, are as defined previously. The two alkyl groups        may comprise a different carbon number from each other. Examples        that may be mentioned include the groups        —(C1-C5)alkylene-N[(C1-C5)alkyl]₂, with —(C1-C5)alkylene- and        —(C1-C5)alkyl as defined above. Advantageously, mention may be        made of the —(CH₂)₃N[(CH₂)₃CH₃]₂ group;    -   an alkene group: a group of formula —C_(n)-H_(2n) in which n is        a natural integer greater than or equal to 2, which may be        linear or branched and which is characterized by the presence of        at least one covalent double bond between two of its carbon        atoms: mention may be made of the ethylene group and the        1,3-butadiene group;    -   an alkyne group: a group of formula C_(n)H_(2n-2) in which n is        a natural integer greater than or equal to 2, which may be        linear or branched and which is characterized by the presence of        at least one covalent triple bond between two of its carbon        atoms. Mention may be made of an acetylene group, a 1-butyne        group or a dimethylacetylene group.    -   leaving group, hereinbelow means a group which can be easily        cleaved from a molecule by breaking a heterolytic bond, with        loss of an electron pair. This group can thus be easily replaced        with another group in a substitution reaction, for example. Such        leaving groups are, for example, halogens or an activated        hydroxyl group, such as a mesyl, tosyl, triflate, acetyl, etc.        Examples of leaving groups and also the references for preparing        them are given in Advances in Organic Chemistry, J. March, 3rd        Edition, Wiley Interscience, pp. 310-316.

According to one embodiment, a subject of the invention is in particulara process for synthesizing a compound of formula (I) for which G3 is—NH-SO2-Rc, G5 is ORb, this compound is referred to as the ketosulfonamidobenzofuran derivative of formula (14) represented below,

in which

G1 represents (i) a linear or branched alkyl group, advantageously aC1-C8 alkyl group and even more advantageously a C1-C4 alkyl group, forinstance a methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl ortert-butyl group, (ii) a haloalkyl group, (iii) a cycloalkyl group, (iv)a substituted or unsubstituted aryl group, (v) an alkene group or (vi)an alkyne group, advantageously, G1 represents an alkyl group and evenmore advantageously G1 represents a methyl or n-butyl group;

and/or

Ra represents a substituent chosen from a hydrogen atom, halogen atomsand alkyl, haloalkyl, alkoxy and alkoxyalkyl groups, advantageously Rarepresents a substituent chosen from a hydrogen atom, halogen atoms andalkyl groups, and even more advantageously Ra represents a hydrogenatom,

and/or

na is equal to 0, 1, 2, 3 or 4, and advantageously na is equal to 0, 1or 4,

and/or

Rb represents a hydrogen atom, an alkyl, haloalkyl, aryl, arylalkyl,heteroaryl, cycloalkyl or heterocycloalkyl group or an-alkyleneaminoalkyl group, advantageously Rb is chosen from-alkyleneaminoalkyl groups, and even more advantageously Rb represents a3-(di-n-butylamino)propyl group;

and/or

Rc represents (a) a linear or branched alkyl group, advantageously aC1-C8 alkyl group and even more advantageously a C1-C4 alkyl group, forinstance a methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl ortert-butyl group, (b) a cycloalkyl group or (c) a substituted orunsubstituted aryl group, advantageously Rc represents an alkyl group oran aryl group, and even more advantageously Rc represents a —CH₃ group;

said process comprising (i) a Friedel-Crafts acylation reaction or (ii)a Fries rearrangement reaction, said reactions taking place startingwith the sulfonamidobenzofuran intermediate of formula (III), i.e. acompound of formula (II) for which G3 represents —NH-SO₂-Rc,

in which G1 and Rc are as defined above and the group G2 is chosen

-   -   from halogen atoms, the —OH group, alkoxy and aryloxy groups and        —NRdRe with Rd and Re being identical or different and being        chosen, independently of each other, from a hydrogen atom, alkyl        groups and aryl groups, said alkyl and aryl groups being        optionally substituted, advantageously G2 is chosen from halogen        atoms, and even more advantageously G2 is chosen from chlorine        and bromine, in the case where said intermediate (II) is engaged        in a Friedel-Crafts reaction;

or

-   -   from the following groups

in which the phenyl is optionally substituted in the ortho and/or metaposition, but never in the para position, with said radical Ra, with Raand na as defined above,

-   -   in the case where said intermediate (II) is engaged in a Fries        reaction.

According to one embodiment, a subject of the invention is in particulara process for synthesizing a compound of formula (I) for which G3 is—NH-SO2-Rc, G5 is ORb, this compound is referred to as the ketosulfonamidobenzofuran derivative of formula (14) represented below,

in which

G1 represents (i) a linear or branched alkyl group, advantageously aC1-C8 alkyl group and even more advantageously a C1-C4 alkyl group, forinstance a methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl ortert-butyl group, (ii) a haloalkyl group, (iii) a cycloalkyl group, (iv)a substituted or unsubstituted aryl group, (v) an alkene group or (vi)an alkyne group, advantageously G1 represents an alkyl group and evenmore advantageously G1 represents a methyl or n-butyl group;

and/or

Ra represents a substituent chosen from a hydrogen atom, halogen atomsand alkyl, haloalkyl, alkoxy and alkoxyalkyl groups, advantageously Rarepresents a substituent chosen from halogen atoms and alkyl groups, andeven more advantageously Ra represents a hydrogen atom,

and/or

na is equal to 0, 1, 2, 3 or 4, and advantageously na is equal to 0, 1or 4,

and/or

Rb represents a hydrogen atom, an alkyl, haloalkyl, aryl, arylalkyl,heteroaryl, cycloalkyl or heterocycloalkyl group or an-alkyleneaminoalkyl group, advantageously Rb is chosen from-alkyleneaminoalkyl groups, and even more advantageously Rb represents a3-(di-n-butylamino)propyl group;

and/or

Rc represents (a) a linear or branched alkyl group, advantageously aC1-C8 alkyl group and even more advantageously a C1-C4 alkyl group, forinstance a methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl ortert-butyl group, (b) a cycloalkyl group or (c) a substituted orunsubstituted aryl group, advantageously Rc represents an alkyl group oran aryl group, and even more advantageously Rc represents a —CH₃ group;

said process comprising a Friedel-Crafts acylation reaction, saidreaction taking place starting with the sulfonamidobenzofuranintermediate of formula (III), i.e. a compound of formula (II) for whichG3 represents —NH-SO₂-Rc,

in which G1 and Rc are as defined above and the group G2 is chosen fromhalogen atoms, the —OH group, alkoxy and aryloxy groups and —NRdRe withRd and Re being identical or different and being chosen, independentlyof each other, from a hydrogen atom, alkyl groups and aryl groups, saidalkyl and aryl groups being optionally substituted, advantageously G2 ischosen from halogen atoms, and even more advantageously G2 is chosenfrom chlorine and bromine,

According to one embodiment, the group G2 in the intermediate of formula(II) or (III) is chosen from —OH, optionally substituted —Ophenyl,chlorine and bromine.

According to one embodiment, said keto sulfonamidobenzofuran derivativeof formula (14) contains a radical Ra which is a hydrogen atom, an nawhich is equal to 4, a radical Rc which is a methyl or phenyl group, aradical G1 which is an n-butyl group and/or a radical Rb which is a—(CH₂)₃N[(CH₂)₃CH₃]₂ group or a —(CH₂)₃N⁺H[(CH₂)₃CH₃]₂, Cl⁻ group.

According to one embodiment, said keto sulfonamidobenzofuran derivativeof formula (14) is dronedarone of formula (D) in free base or salt form,advantageously in hydrochloride form.

The first part of the synthesis according to the invention, asrepresented in scheme 2 below, consists of an oxidation reaction of aphenolic derivative (V) to a p-quinone derivative (VI) in which G4 ischosen from (i) groups =NSO₂alkyl, (ii) groups =NSO₂aryl and (iii)groups =NRc in which Rc is chosen from hydrogen, alkyl or aryl groupsand haloalkyl groups, advantageously the group G4 represents a group=NSO₂alkyl, even more advantageously the group G4 represents a group=NSO₂CH₃.

Oxidizing agents for this oxidation reaction in accordance with theinvention that may be mentioned include:

-   -   sodium or potassium dichromate, (K₂Cr₂O₇, Na₂Cr₂O₇),    -   activated manganese dioxide, (MnO₂)    -   iodylbenzene (C₆H₅I₂),    -   iodosylbenzene (C₆H₅IO), and    -   lead tetraacetate, (Pb(OAc)₄),    -   chromate-based reagents, such as Collins' reagents, Jones'        reagent, Ag₂O, peroxides such as dicumyl peroxide, cumene        hydroperoxide, etc.; DMSO, DDQ (dichlorodicyanoquinone),        peracids such as chloroperbenzoic acid, other perbenzoic acids;        hypervalent iodine reagents (Ph- I (OAc)2, etc.), hydrogen        peroxide, oxygen (air), bleach, supported oxidizing agents,        electrolytic processes,

in, for example, solvents such as glacial acetic acid, ethyl acetate,acetone, acetonitrile, pyridine, chlorinated solvents such aschlorobenzene or dichloromethane, aromatic solvents such as benzene,linear or cyclic alkanes, water, DMSO, DMAP, and carboxylic acids suchas acetic acid.

Examples that may thus be mentioned include:

-   -   an oxidation reaction with sodium dichromate monohydrate in 20%        sulfuric acid for about 1 hour at room temperature, or    -   an oxidation reaction with about 0.333 equivalent of potassium        dichromate and about 1.333 equivalents of sulfuric acid per        approximately 1 equivalent of phenolic derivative,    -   an oxidation reaction with an acetic acid solution containing        about 0.5 equivalent of potassium dichromate per approximately 1        equivalent of phenolic derivative,    -   an oxidation reaction performed with heating with 1 to 4        equivalents, for example about 1 or 4 equivalents of activated        MnO₂ (relative to the aminophenol engaged) in benzene, or    -   an oxidation reaction, which is performed over a few tens of        minutes, with a large excess of MnO₂ (about 7 equivalents and        more) in dichloromethane or acetonitrile at room temperature,    -   an oxidation reaction with iodylbenzene (C₆H₅IO₂), the        reactivity of which is increased by catalysis with a Lewis acid        (for example: vanadyl acetylacetonate) in refluxing benzene or        toluene for about 4 hours. Iodylbenzene is not commercially        available, and needs to be synthesized beforehand from        iodobenzene. Several synthetic processes are described mainly        using sodium hypochlorite in acetic acid.    -   an oxidation reaction in the presence of about 2.5 equivalents        of iodosylbenzene (C₆H₅IO) in methanol over a molecular sieve (4        Å) for about 1 hour of stirring at about 0° C.

Sodium and potassium dichromates are common reagents that are lessexpensive and less toxic than lead tetraacetate.

The oxidation reaction that appears to be the most advantageous isobtained with MnO₂ in acetic acid. From the start, the reaction iscomplete with this oxidizing agent. In addition, the low toxicity ofMnO₂, compared with that of Pb(OAc)₄, is reduced.

Advantageously, the oxidation reaction of the phenolic derivative (V) tothe p-quinone derivative (VI) is performed with K₂Cr₂O₇ or MnO₂ asoxidizing agent in acetic acid.

Next, a coupling reaction of said quinoneimine derivative (VI) with adicarbonyl derivative (VII) takes place, in the presence of a base, forinstance a strong base such as, for example, an alkoxide. This reactionmay take place, for example, in an aprotic solvent such as DMF ordioxane at room temperature.

The dicarbonyl derivative (VIII) is then engaged in a cyclizationreaction to give a benzodihydrofuran derivative (IX), which, bydehydration, will then lead to the aromatic benzofuran derivative (II).This reaction may take place, for example, in an aprotic solvent such asDMF or dioxane. The cyclization/dehydration may take place in strongacid medium, for example using hot hydrochloric acid for 3 hours.

The groups G1, G2 and/or G3 of compounds (V), (VII), (VIII), (IX) and(II) of scheme 3 above are as defined for the keto benzofuran of formula(I) in accordance with the invention.

The keto benzofuran derivative (I) is then obtained from said aromaticbenzofuran intermediate derivative (II) either via a Friedel-Craftsacylation route A or via a Fries rearrangement route B.

According to one embodiment, the first part of the synthesis accordingto the invention, as represented in scheme 3 below, consists insynthesizing an intermediate (7). Said intermediate is thesulfonamidobenzofuran ester of formula (7) below:

in which Rc and G1 are as defined above and Ri represents a hydrogenatom, an alkyl or an aryl, and is advantageously a methyl, an ethyl or aphenyl. This intermediate (7) may thus be obtained after the followingsuccessive steps, represented in scheme 3:

-   -   Sulfonylation of the p-aminophenol of formula (1);    -   Oxidation of the p-aminosulfonylphenol (2) obtained in the        preceding step to the p-quinone sulfonimide of formula (3), i.e.        a compound of formula (VI) for which G4 represents =N-SO₂-Rc;    -   Coupling of said p-quinone sulfonimide of formula (3) with a        β-keto ester of formula (4), i.e. a compound of formula (VII)        for which G2 represents —ORi;    -   Cyclization of the sulfonamido keto ester benzofuran (5), i.e. a        compound of formula (VIII) for which G2 represents —ORi and G3        represents —NH-SO₂-Rc, leading to the formation of the        sulfonamido-hydroxybenzofuran (6), i.e. a compound of        formula (IX) for which G2 represents —ORi and G3 represents        —NH-SO₂-Rc;    -   Dehydration/aromatization of the        sulfonamido-hydroxybenzofuran (6) allowing the formation of the        benzofuran aromatic nucleus of the sulfonamidobenzofuran ester        of formula (7).

The groups G1 and/or Rc of compounds (2), (3), (4), (5), (6) and (7) ofscheme 3 above are as defined for the keto benzofuran of formula (I)according to the invention and Ri is as defined for compound (7) above.

The sulfonylation reaction of the p-aminophenol (1) to thep-sulfonamidophenol (2) may be performed using RcS(O)₂Cl, with Rc asdefined above, in the presence of a base. Document J. Am. Chem. Soc,1951, 73, 1145-1149 by R. Adams and J. H. Looker describes the operatingconditions enabling such a sulfonylation and oxidation.

In the case where Rc=—CH₃, it is p-methanesulfonamidophenol obtainedfrom the p-aminophenol (1) mesylated with methanesulfonyl chloride inthe presence of a base. In the case where Rc=—C₆H₅, it isp-benzenesulfonamidophenol obtained from the p-aminophenol (1)sulfonylated with benzenesulfonyl chloride in the presence of a base.

The reaction solvent may be chosen, for example, from methanol, ethanol,pyridine, dimethylformamide (abbreviated DMF), dichloromethane,chloroform, chlorobenzene, dichloroethane, benzene, toluene, ethylacetate, acetonitrile, acetone, tetrahydrofuran (abbreviated THF),dioxane and N-methylpyrrolidinone, and advantageously it is chosen frompyridine, methanol, DMF and N-methylpyrrolidinone.

The base may be chosen, for example, from pyridine, triethylamine,hydrogen carbonates, potassium carbonate, sodium carbonate, sodiumhydroxide and ammonia, and advantageously potassium or sodium carbonate.

The reaction is preferably performed at a temperature below roomtemperature.

According to one embodiment, RcS(O)₂Cl is methanesulfonyl chloride orbenzenesulfonyl chloride.

This sulfonylation reaction may advantageously be performed with 1equivalent of methanesulfonyl chloride poured between 10° C. and 15° C.onto 2 equivalents of p-aminophenol suspended in slightly more than 11volumes of methanol (volume in ml/weight in g of p-aminophenol). Thesecond equivalent of p-aminophenol serves to take up the acid formed,the amine function acting as a base.

It may also take place in methanol by adding an equivalent ofmethanesulfonyl chloride and by slowly neutralizing up to pH=6 withNaHCO₃.

The p-sulfonamidophenol (2) then undergoes an oxidation reaction leadingto the formation of p-quinone monoimide (3): when Rc=—CH₃, it isp-methanesulfonamidophenol and when Rc=—C₆H₅, it isp-benzenesulfonamidophenol.

This oxidation reaction may be performed, for example, using:

-   -   (i) lead tetraacetate, advantageously using lead tetraacetate in        acetic acid,    -   (ii) sodium or potassium dichromate (or K₂Cr₂O₇), advantageously        using sodium dichromate monohydrate in sulfuric acid or acetic        acid,    -   (iii) activated manganese dioxide, advantageously MnO₂ in        glacial acetic acid, ethyl acetate, acetone, acetonitrile,        pyridine, chlorinated solvents such as chlorobenzene or        dichloromethane, aromatic solvents such as benzene, linear or        cyclic alkanes, water, DMSO, DMAP, and carboxylic acids such as        acetic acid.    -   or    -   (iv) iodylbenzene (C₆H₅IO₂) or iodosylbenzene (C₆H₅IO),        advantageously iodylbenzene (C₆H₅IO₂) in the presence of a Lewis        acid, for instance vanadyl acetylacetonate, in benzene or        toluene.

According to one embodiment, sodium or potassium dichromate,advantageously K₂Cr₂O₇ in acetic acid, or activated manganese dioxideare used.

The p-quinone monoimide (3) then undergoes a coupling reaction with:

-   -   the keto ester of formula (4) with G1 and Ri as defined above;        advantageously, it is ethyl acetoacetate or methyl        3-oxoheptanoate,    -   advantageously in the presence of a base.

Dioxane or acetone may be mentioned as suitable solvent for thiscoupling reaction. Alkoxides such as, for example, sodium methoxide,lithium methoxide, sodium ethoxide and lithium ethoxide may be mentionedas suitable base.

When G1=n-butyl and Ri=methyl or phenyl, the keto ester (4) is thenmethyl or phenyl 3-oxoheptanoate, which, by coupling reaction withp-methanesulfonamidophenol, gives directly methyl or phenyl2-n-butyl-5-methanesulfonamidobenzofuran-3-carboxylate.

Specifically, the substituted aminophenol resulting from the precedingcoupling, of formula (5), is then cyclized in acidic medium,advantageously in the presence of hydrochloric acid, phosphoric acid,sulfuric acid, methanesulfonic acid, trifluoroacetic acid or aceticanhydride, leading, after dehydration and aromatization, to thesulfonamidobenzofuran ester (7).

The second part of the synthesis may be performed using thesulfonamidobenzofuran ester intermediate (7) via two possible routes:route A comprising a Friedel-Crafts acylation step or route B comprisinga Fries rearrangement step, represented in scheme 4 below, both leadingto the formation of the keto benzofuran (14) in accordance with theinvention.

ROUTE A: Friedel-Crafts Acylation

According to one embodiment, the synthetic process according to theinvention is characterized in that the sulfonamidobenzofuran ester offormula (7) is engaged in a Friedel-Crafts route A as represented abovein scheme 4, successively comprising a step:

-   -   of saponification of the ester function of the        sulfonamidobenzofuran ester of formula (7), leading to the        formation of the sulfonamidobenzofuran acid (8);    -   of formation of a sulfonamidobenzofuran acyl halide of formula        (9), advantageously the sulfonamidobenzofuran acyl bromide of        formula (9′) or the sulfonamidobenzofuran acyl chloride of        formula (9″) from said sulfonamidobenzofuran acid (8);    -   of Friedel-Crafts acylation of the aromatic ether (13) with Rb,        Ra and na as defined above, with said sulfonamidobenzofuran acyl        halide of formula (9), in particular the sulfonamidobenzofuran        acyl bromide of formula (9′) or the sulfonamidobenzofuran acyl        chloride of formula (9″), leading to the formation of said keto        sulfonamidobenzofuran derivative of formula (14) according to        the invention.

In the case of route A, the sulfonamidobenzofuran ester intermediate (7)bearing in position 3 an ester function is saponified with, for example,10 weight % sodium hydroxide, giving the sulfonamidobenzofuran acid offormula (8) or the sodium salt thereof represented in scheme 4. Thissulfonamidobenzofuran acid of formula (8) is then activated so as to beable to be engaged with the aromatic ether intermediate (13) in aFriedel-Crafts acylation reaction.

This activation consists in transforming the sulfonamidobenzofuran acidof formula (8) into a sulfonamidobenzofuran acyl halide of formula (9),advantageously the sulfonamidobenzofuran acyl bromide of formula (9′)and the sulfonamidobenzofuran acyl chloride of formula (9″).

According to one embodiment, the sulfonamidobenzofuran acid of formula(8) is transformed into the sulfonamidobenzofuran acyl chloride offormula (9″) by reaction with thionyl chloride or oxalyl chloride.

According to another embodiment, the sulfonamidobenzofuran acid offormula (8) is transformed into the sulfonamidobenzofuran acyl bromideof formula (9′) by reaction with thionyl bromide or oxalyl bromide.

Another possibility is to perform the Friedel-Crafts reaction with acompound of formula PhOR' (R′=alkyl or a leaving group). In this case,starting with the compound of formula (9), a compound of formula (14) isobtained, with Rb=R′ which may be, for example, a methyl group. IfRb=R′=H, the compound of formula (12) is obtained directly.

Aromatic ether compounds that may advantageously be mentioned includephenol (Rb=H) (13), N,N-diethyl-N-(2-phenoxyethyl)amine in free baseform, in hydrochloride form or any other salt of this amine,N,N-di-n-butyl-N-(2-phenoxypropyl)amine in free base form, inhydrochloride form or any other salt of this amine, phenol, andalkoxybenzenes (anisole, ethoxybenzene, ROPh with R being resistant inacidic medium and labile in basic medium, etc.).

The aromatic ether (13) may be obtained by reacting (i) phenol with (ii)a compound RbX in which Rb is as defined above and X is a leaving group,advantageously a halogen, better still a chloride or a bromide, (iii) inthe presence of a base, for instance sodium hydroxide, and then bytransforming the aromatic ether (13) obtained into a salt,advantageously into the hydrochloride salt. Advantageously, RbX is atertiary amine halide, and even more advantageously RbX isCl-(CH₂)₃N[(CH₂)₃CH₃]₂ or Br-(CH₂)₃N[(CH₂)₃CH₃]₂.

According to one embodiment, the coupling of the phenol takes place withN-(3-chloropropyl)-N, N-dibutylamine, givingN,N-dibutyl-N-(3-phenoxypropyl)amine. According to one embodiment,N,N-dibutyl-N-(3-phenoxypropyl)amine is salified toN,N-dibutyl-N-(3-phenoxypropyl)amine hydrochloride.

The Friedel-Crafts acylation of the aromatic ether compound (13), infree base or hydrochloride form, with the acylsulfonamidobenzofuranhalide of formula (9) is catalyzed with a Lewis acid.

Examples of Lewis acids that may be mentioned include SnCl₄, AlCl₃,FeCl₃, TiCl₄, BF₃ and Tf₂O (triflic anhydride).

According to one embodiment, the Friedel-Crafts acylation reaction ofthe aromatic ether compound (13) in free base form takes place in thepresence of SnCl₄ as Lewis acid.

According to another embodiment, the Friedel-Crafts acylation reactionof the aromatic ether compound (13) in hydrochloride form takes place inthe presence of AlCl₃ as Lewis acid.

The Friedel-Crafts acylation reaction may be conducted in a solvent ofthe type such as dichloromethane, chlorobenzene, nitrobenzene, tolueneor xylene.

This reaction leads to the production of the keto sulfonamidobenzofuran(14), advantageously said keto sulfonamidobenzofuran in free base formin which Rc=—CH₃, G1=—nBu, Ra=H, na=4 and Rb=—C₃H₆N(Bu)₂, and even moreadvantageously the keto sulfonamidobenzofuran in hydrochloride form inwhich Rc=—CH₃, G1=—nBu, Ra=H, na=4 and Rb=—C₃H₆N⁺(Bu)₂.

The Friedel-Crafts acylation reaction has the advantage of deactivatingthe aromatic nucleus engaged in this reaction, thus preventing multipleacylations.

According to a particularly advantageous embodiment represented inscheme 5 below, the Friedel-Crafts acylation takes place with (i) theacylsulfonamidobenzofuran halide of formula (9d), in particular theacylsulfonamidobenzofuran bromide of formula (9d) with halogen =Br orthe acylsulfonamidobenzofuran chloride of formula (9d) with halogen =Cl,and (ii) with N,N-dibutyl-N-(3-phenoxypropyl)amine hydrochloride offormula (16d), which is itself obtained by reacting phenol (15) withN-(3-chloropropyl)-N,N-dibutylamine in the presence of sodium hydroxidein water, said acylation reaction leading to the formation ofdronedarone of formula (D) according to the invention, which, at the endof the Friedel-Crafts reaction, may be isolated directly inhydrochloride form or may be isolated in base form and may subsequentlybe readily converted into pharmaceutically acceptable salts by additionto organic or mineral acids as defined above, in particular intohydrochloride by reaction with 36% hydrochloric acid at a temperaturebelow 50° C.

However, the synthesis of keto sulfonamidobenzofuran derivatives offormula (I) according to the invention, and in particular of ketosulfonamidobenzofuran derivatives of formula (14), such as dronedaroneof formula (D), may also take place via a Fries rearrangement accordingto route B described below.

ROUTE B: Fries Rearrangement

According to one embodiment, the synthetic process according to theinvention is characterized in that the sulfonamidobenzofuran ester offormula (5) is engaged in a Fries route B as represented above in scheme4, successively comprising a step:

-   -   of Fries rearrangement of the sulfonamidobenzofuran ester of        formula (7) for which Ri is a phenyl group, optionally        substituted in the ortho and/or meta position but never in the        para position, with a group Ra chosen from halogen atoms and        alkyl, haloalkyl, alkoxy and alkoxyalkyl groups, into the keto        sulfonamidobenzofuran of formula (12);    -   of coupling of the keto sulfonamidobenzofuran of formula (12)        with a compound RbX as defined above, advantageously an amino        halide RbX, leading to the keto sulfonamidobenzofuran derivative        of formula (14).

According to a particularly advantageous embodiment represented inscheme 6 above, the Fries reaction takes place with the intermediate offormula (7d) for which G1 represents an n-butyl group, leading to theformation of compound (12d), which, after nucleophilic substitution withCl(CH₂)₃N(Bu)₂, results in the formation of dronedarone of formula (D).Dronedarone may then be readily converted into pharmaceuticallyacceptable salts by addition to organic or mineral acids as definedabove, in particular into hydrochloride salts by reaction with 36%hydrochloric acid at a temperature below 50° C.

The Fries reaction may take place, for example, in a solvent such aschlorobenzene with 4 equivalents of aluminum chloride AlCl₃ at atemperature of about 90-95° C. for 13 to 17 hours.

The process according to the invention in particular has the followingadvantages:

-   -   convergent synthesis;    -   limited number of synthetic steps;    -   possibility of performing in sequence several steps not        requiring the isolation of the products obtained;    -   reactions that are simple and technologically easy to perform;    -   no hydrogenation step to obtain an amino function in position 5        of the benzofuran;    -   common, readily available and inexpensive starting materials and        reagents.

The invention will now be described in greater detail.

EXAMPLES

The procedures and examples below describe the preparation of thedronedarone intermediate. These procedures and examples are not limitingand merely serve to illustrate the present invention. In the proceduresand examples below:

-   -   the NMR (nuclear magnetic resonance) spectra are acquired on a        Fourier transform spectrometer (BrUker) at 300 MHz (exchangeable        protons not recorded);    -   s=singlet,    -   d=doublet,    -   m=multiplet,    -   br=broad signal,    -   t=triplet,    -   q=quartet,    -   DMSO-d₆=deuterated dimethyl sulfoxide.    -   CDCl₃=deuterated chloroform.

The solvent mixtures are quantified in volumetric ratios.

The NMR spectra and mass spectra confirm the structures of the compoundsobtained according to the examples below.

-   -   The retention times by HPLC analysis are in minutes.

The HPLC conditions used are as follows:

Column: Xterra RP18 3.5 μm, 100 mm*4.6 mm. mobile phase: A - 0.01MKH₂PO₄ buffer B - Acetonitrile Flow rate: 1.0 ml/min. Gradient: Time(min) % A % B  0 80 20 15 25 75 25 25 75 27 80 20 37 80 20 Detector: UVat 226 nm Injection: 10 μl of product in dioxane/H₂O (95/5) Retention:Product retention times 2.6 min p-methanesulfonamidophenol 3.4 minp-quinone monomethanesulfonimide 10.6 min dronedarone HCl 11.3 min2-butyl-5-(methanesulfonamido)benzofuran-3-carbonyl chloride

In the examples that follow, the following abbreviations are used:

-   -   h: hours    -   min: minutes    -   eq: equivalent    -   DMF: N,N-dimethylformamide    -   MTBE: methyl tert-butyl ether    -   DCE: dichloroethane    -   DCM: dichloromethane    -   DMSO: dimethyl sulfoxide    -   RT: room temperature (between 20 and 25° C.)    -   m.p.: melting point    -   Yld: yield    -   HCl: hydrochloric acid    -   Lit.: literature, especially R. Adams and J. H. Looker, J. Am.        Chem. Soc., 1951, 73, 1145-9    -   Mass yield=obtained mass expected mass

In the general synthetic schemes which follow, the starting compoundsand the reagents, when the method for preparing them is not described,are commercially available or described in the literature, or else canbe prepared according to methods which are described therein or whichare known to those skilled in the art.

Example 1 Synthesis of p-methanesulfonamidophenol (orN-(4-hydroxyphenyl)methanesulfonamide) according to method I

5.4 g (49.5 mmol) of p-aminophenol are dissolved in 40 ml of anhydrouspyridine, and 5.7 g (1 equivalent) of methanesulfonyl chloride dilutedin 12 ml of pyridine are added over 15 minutes at 20° C. under a streamof nitrogen. The reaction medium is stirred for 3 days at 20° C. and isthen poured into 1.5 liters of water containing a sufficient amount ofhydrochloric acid (67 g of 36% HCl) to neutralize the pyridine and toestablish a pH 1.5. The aqueous phase is separated out by settling andextracted twice with 250 ml of ethyl acetate. The organic phases arecombined and washed with twice 250 ml of water and then concentratedunder vacuum. The residue is recrystallized from 40 ml of ethyl acetate.The crystals are filtered off at 0° C. and washed with 15 ml of ethylacetate. 2.14 g of crude p-methanesulfonamidophenol are obtained.

Mass yield: 23% by weight

m.p.: 156.5° C. (lit. 154.5-155.5° C.)

¹H NMR (DMSO) δ 3.08 (s, 3H, CH₃S), 6.74 (d, 2H, CH_(arom)), 7.02 (d,2H, CH_(arom)), 9.26 (broad s, 2H, OH and NH); ¹³C NMR (DMSO) δ 38.3(1-CH₃), 115.5, 124.0 (4-CH_(arom)), 129.0 (1-C_(arom)-N), 154.8(1-C_(arom)-O).

Synthesis of p-methanesulfonamidophenol (orN-(4-hydroxyphenyOmethanesulfonamide) according to method II

10 g (91.6 mmol) of p-aminophenol are dissolved in 250 ml of methanolsupplemented with 0.5 ml of 36% hydrochloric acid. The mixture isstirred vigorously and 10.6 g (1 eq.) of methanesulfonyl chloride areadded at between 20 and 23° C., over 10 minutes. The mixture ismaintained for 1 hour at 20-23° C. and is then neutralized very slowly(over 2 hours) to pH 5.5-6 by adding sodium hydrogen carbonate (8.2 g intotal). The mixture is maintained for 30 minutes and is then acidifiedwith 5 ml of 36% hydrochloric acid. The salts formed are removed byfiltration and the reaction medium is concentrated under vacuum to aresidual volume of 35 ml. 100 ml of 1N hydrochloric acid are then addedand the mixture is concentrated again to a residual volume of 95 ml inorder to remove the residual methanol. The precipitated product (13.3 g,75.6%) is recovered by filtration and the filtration mother liquors areextracted with 3 times 50 ml of ethyl acetate. Concentrating the ethylacetate to dryness gives a further 1.9 g (11.6%).

Total yield: 87.2% by weight

m.p.: 157.1° C. (lit. 154.5-155.5° C.)

Example 2 Synthesis of p-benzenesulfonamidophenol (orN-(4-hydroxyphenyl)benzenesulfonamide)

The same procedure as above (Example 1) is followed, starting with 10.9g (0.1 mol) of p-aminophenol in 40 ml of anhydrous pyridine and 18 g (1equivalent) of benzenesulfonyl chloride. 14.8 g ofp-benzenesulfonamidophenol are obtained.

Mass yield: 59.4% by weight

m.p.: 156° C. (lit. 154.5-155.5° C.)

¹H NMR (DMSO) δ 6.6 (d, 2H_(arom)), 6.8 (d, 2H_(arom)), 7.5 (m,5H_(arom)), 9.3 and 9.7 (2 broad s, OH and NH); ¹³C NMR (DMSO) δ 115.4,124.0, 126.6, 128.9, 132.9 (9-CH_(arom)) 128.3 (1-C_(arom-N)), 139.5(1-C_(arom)-S), 154.8 (1-C_(arom)-O).

Example 3 Synthesis of p-quinone monomethanesulfonimide orN-(4-oxocyclohexa-2,5- dien-1-ylidene)methanesulfonamide) by oxidationof p-methanesulfonamidophenol with K₂Cr₂O₇

0.8 g (2.72 mmol) of K₂Cr₂O₇ is stirred for 1 hour at 20° C. in 20 ml ofacetic acid. The dissolution remains partial. 1 g (5.34 mmol) ofp-methanesulfonamidophenol is added and the mixture is stirred for 2hours 30 minutes at 20° C. Next, 40 ml of water are added and thereaction medium is rapidly extracted with 3 times 25 ml ofdichloromethane. The organic phases are combined and washed with 25 mlof water. On concentrating to dryness, 0.85 g of product is obtained.

Mass yield: 86% by weight

¹H NMR (DMSO) δ 3.41 (s, 3H), 6.83 (m, 2H, CH_(arom)), 7.17 (m, 1H,CH_(arom)), 7.84 (m, 1H, CH_(arom)); ¹³C NMR (DMSO) δ 42.5 (1-CH₃),129.5, 135.6, 136.0, 139.9 (4-CH), 164.2 (1-C=N), 186.0 (1-C=O).

Synthesis of p-quinone monomethanesulfonimide by oxidation ofp-methanesulfonamidophenol with MnO₂

A mixture containing 20 g (0.107 mol) of p-methanesulfonamidophenol, 44g (4 eq.) of activated 85% MnO₂ and 300 ml (15 vol.) of acetic acid isstirred at 25±5° C. for 45 minutes, and the insoluble matter is thenfiltered off and washed with twice 150 ml of acetic acid. The filtrationmother liquors and the washing waters are combined and concentratedunder vacuum. The residue is taken up with 300 ml of dichloromethane.The undissolved matter is removed by filtration and washed with 100 mlof dichloromethane. Concentrating the dichloromethane phases undervacuum gives 13.6 g of p-quinone monomethanesulfonimide.

Mass yield: 68.7%.

Melting point in accordance with the literature (134° C.).

The retention time by HPLC analysis is identical to that of p-quinonemonomethanesulfonimide obtained via the method of R. Adams et al.

OR

A mixture containing 30 g (0.160 mol) of p-methanesulfonamidophenol, 18g (1.1 eq.) of activated 85% MnO₂ and 450 ml (15 vol.) of acetic acid isstirred at 25±5° C. for 1 hour, and the insoluble matter is thenfiltered off and washed with four times 200 ml of acetic acid. Thefiltration mother liquors and the washing waters are combined andconcentrated under vacuum. The residue is taken up in a mixture of 600ml of dichloromethane and 250 ml of water. The phases are separated bysettling, the organic phase is retained and the aqueous phase isre-extracted with 150 ml of dichloromethane. The combineddichloromethane phases are concentrated under vacuum and the solidobtained is taken up in 250 ml of ethanol. The product is filtered offand dried under vacuum. 27.06 g of p-quinone monomethanesulfonimide areobtained.

Mass yield: 91.5%.

Melting point in accordance with the literature (134° C.).

The retention time by HPLC analysis is identical to that of p-quinonemonomethanesulfonimide obtained via the method of R. Adams et al.

Example 4 Synthesis of ethyl2-[5-(benzenesulfonamido)-2-hydroxyphenyl]-3-oxo-butanoate

A mixture containing 1 g (3.7 mmol) of p-quinone monobenzenesulfonimideand 0.55 g (1.1 eq.) of ethyl acetoacetate in 20 ml of 1,4-dioxane isstirred at 20±3° C. for 5 minutes, followed by addition of 30 mg ofsodium methoxide (powder). The reaction medium is continuously stirredat 20° C. for 30 minutes and then filtered and concentrated under vacuumto remove half of the solvent, and 130 ml of methylcyclohexane are addedin portions of 30 to 50 ml alternating with distillation in order toremove the dioxane azeotropically. The oil formed is taken up in 100 mlof ethanol and concentrated to a residual volume of 10 ml. The residueis cooled to 0° C. for 1 hour, and the crystals are filtered off andwashed with twice 3 ml of ethanol at 0° C. 0.5 g of crude product isobtained.

Mass yield: 35.6% by weight

¹H NMR (DMSO) δ 1.15 (t, 3H, CH₃), 1.96 (s, 3H, CH₃), 4.09 (q, 2H, CH₂),4.98 (s, 1H, CH), 6.73 (d, 1H, CH_(arom)), 6.74 (d, 1H, CH_(arom)), 6.87(dd, 1H, CH_(arom)), 7.41 to 7.61 (m, 5H, CH_(arom)), 9.77, 9.82 (2broad s, 2H, NH and OH); ¹³C NMR (DMSO) δ 13.8 (1-CH₃), 28.6 (1-CH₃),57.8 (1-CH), 60.8 (1-CH₂), 115.4, 123.7, 123.8 (3-CH_(arom)), 120.2,128.5, 139.2, 152.4 (4-C_(arom)), 126.5, 128.9, 132.5 (5-CH_(arom)),168.3, 201.8 (2-C=O).

Example 5 Synthesis of ethyl 5-benzenesulfonamido-2-methylbenzofuran-3-carboxylate (or ethyl5-(benzenesulfonamido)-2-methylbenzofuran-3-carboxylate)

0.25 g of the product obtained previously is stirred in 12.5 ml of 20%hydrochloric acid for 3 hours at reflux and then filtered at 0° C. andwashed with 4 ml of ice-cold water. 0.24 g of crude ethyl5-benzenesulfonamido-2-methylbenzofuran-3-carboxylate is obtained.

Mass yield: 100%

¹H NMR (DMSO) δ 1.34 (t, 3H, CH₃), 2.66 (s, 3H, CH₃), 4.29 (q, 2H, CH₂),7.04 (dd, 1H, CH_(arom)), 7.46 (d, 1H, CH_(arom)), 7.64 (d, 1H,CH_(arom)), 7.48 to 7.61 and 7.70 to 7.76 (m, 5H, CH_(arom)), 10.3 (s,1H, NH); ¹³C NMR (DMSO) δ 14.0 (2-OH₃), 60.0 (1-CH₂), 111.3, 113.5,118.4 (3-CH_(arom)), 108.1, 125.9, 133.8, 139.2, 150.0 (5-C_(arom)),126.6, 129.1, 132.7 (5-CH_(arom)).

Example 6 Synthesis of ethyl2-[2-hydroxy-5-(methanesulfonamido)phenyl]-3-oxobutanoate

The procedure is performed in the same manner as previously in Example4, with 1 g (5 mmol) of p-quinone monomethanesulfonimide obtained from1.75 g of substituted p-methanesulfonamidophenol in oil form.

¹H NMR (DMSO) δ 1.18 (t, 3H, CH₃), 2.13 (s, 3H, CH₃), 2.84 (s, 3H,CH₃S), 4.12 (q, 2H, CH₂), 5.10 (s, 1H, CH), 6.84 (d, 1H, CH_(arom)),6.97 (d, 1H, CH_(arom)), 7.03 (dd, 1H, CH_(arom)), 9.77, 9.82 (2 broads, 2H, NH and OH); ¹³C NMR (DMSO) δ 13.8 (1-CH₃), 28.9 (1-CH₃), 38.2(1-CH₃), 58.0 (1-CH), 60.8 (1-CH₂), 115.5, 123.4, 123.8 (3-CH_(arom)),120.4, 129.2, 152.4 (3-C_(arom)), 154.8 (1-C_(arom)-O), 168.4, 201.9(2-C=O).

Example 7 Synthesis of5-methanesulfonamido-2-methylbenzofuran-3-carboxylic acid (or5-(methanesulfonamido)-2-methylbenzofuran-3-carboxylic acid)

1 g of the product obtained in Example 6 is cyclized in 40 ml of acetoneand 25 ml of 36% HCl. The mixture is refluxed for 12 hours and thenconcentrated under vacuum and the residue is taken up in 10 ml of 10%sodium hydroxide and stirred at 30° C. for 1 hour (saponification of theester part). The aqueous phase is extracted with 10 ml of DCM and thenacidified to pH<4 with 36% HCl solution. The precipitate is filteredoff. 0.64 g of crude 5-methanesulfonamido-2-methylbenzofuran-3-carboxylic acid is obtained.

Mass yield: 74.4%

¹H NMR (DMSO) δ 2.70 (s, 3H, CH₃), 2.91 (s, 3H, CH₃S), 7.21 (dd, 1H,CH_(arom)), 7.55 (d, 1H, CH_(arom)), 7.81 (d, 1H, CH_(arom)), 13.04 (s,1H, NH); ¹³C NMR (DMSO) δ 14.1 (1-CH₃), 38.5 (1-CH₃), 111.2, 113.7,118.5 (3-CH_(arom)), 108.9, 126.7, 134.4, 150.1 (4-C_(arom)), 164.0,164.7 (2-C).

Example 8 Synthesis of methyl2-[2-hydroxy-5-(methanesulfonamido)phenyl]-3-oxoheptanoate

A mixture containing 2 g (10.8 mmol) of p-quinone monomethanesulfonimideand 1.88 g (1.1 eq.) of methyl 3-oxoheptanoate in 50 ml of 1,4-dioxaneis stirred at 20° C. ±3° C., followed by addition of 50 mg of sodiummethoxide (powder), and stirring is continued for 30 minutes. Thereaction medium is filtered and the residue is taken up in 40 ml ofacetone.

¹H NMR (DMSO) δ 0.79 (t, 3H, CH₃), 1.18 (m, 2H, CH₂), 1.42 (quintet, 2H,CH₂), 2.49 (m, 2H, CH₂), 2.84 (s, 3H, CH₃), 3.65 (s, 3H, CH₃), 5.16 (s,3H, CH₃), 6.83 (d, 1H, CH_(arom)), 6.97 (d, 1H, CH_(arom)), 7.03 (dd,1H, CH_(arom)), 9.22, 9.85 (2 broad s, 2H, NH and OH); ¹³C NMR (DMSO) δ13.5 (1-CH₃), 21.3 (1-CH₂), 25.1 (1-CH₂), 38.2 (1-CH₃), 40.6 (1-CH₂),52.1 (1-CH and 1-CH₃O), 115.5, 123.4, 123.9 (3-CH_(arom)), 120.2, 128.8,152.3 (3-C_(arom)), 168.9, 204.0 (2-CO).

Example 9 Synthesis of2-butyl-5-methanesulfonamidobenzofuran-3-carboxylic acid (or2-butyl-5-(methanesulfonamido)benzofuran-3-carboxylic acid) according tomethod I

70 ml of acetone and 57.5 ml of 36% hydrochloric acid are added to 20 mlof the acetone-based solution obtained after Example 8. This mixture isrefluxed for 5 hours and then concentrated under vacuum. The residue isstirred for 1 hour in the presence of 220 ml of 10% sodium hydroxidesolution (pH=13-14) and then extracted three times with 10 ml of DCM andfinally is precipitated from 36% HCl solution. 1.1 g of crude2-butyl-5-methanesulfonamidobenzofuran-3-carboxylic acid are obtained.

Yield: 66.4% by weight

¹H NMR (DMSO) δ 0.90 (t, 3H, CH₃), 1.33 (sextet, 2H, CH₂), 1.69(quintet, 2H, CH₂), 2.91 (s, 3H, CH₃), 3.15 (t, 2H, CH₂), 7.56 (d, 1H,CH_(arom)), 7.21 (dd, 1H, CH_(arom)), 7.83 (d, 1H, CH_(arom)), 9.61 (s,1H, NH); ¹³C NMR (DMSO) δ 13.4 (1-CH₃), 21.6 (1-CH₂), 26.9 (1-CH₂), 29.3(1-CH₂), 38.5 (1-CH₃), 115.5, 123.4, 123.9 (3-CH_(arom)), 108.7, 126.7,134.3, 150.2 (4-C_(arom)), 164.6, 167.4 (1-C—O and 1-C=O).

Synthesis of 2-butyl-5-methanesulfonamidobenzofuran-3-carboxylic acid(or 2-butyl-5-(methanesulfonamido)benzofuran-3-carboxylic acid)according to method II

The coupling is performed under the same conditions as previously(Example 8), and, after filtering the reaction medium, the crude productis left in the dioxane to perform the cyclization. Hydrochloric acid isadded in the same proportions and the mixture is maintained at atemperature of 50° C. for 1 hour 30 minutes. It is concentrated undervacuum and the residue is taken up in 10% NaOH and stirred at 25° C. for21 hours, and the product is then precipitated out by adding 36% HCl.1.5 g of crude 2-butyl-5-methanesulfonamidobenzofuran-3-carboxylic acidare obtained.

Mass yield: 89.2% by weight

Example 10 Synthesis of2-butyl-5-(methanesulfonamido)benzofuran-3-carbonyl chloride

7 g (22.48 mmol) of 2-butyl-5-methanesulfonamidobenzofuran-3-carboxylicacid are dissolved in 50 g of thionyl chloride and stirred for 3 hoursat 20-25° C. and then refluxed for 30 minutes (79° C.). The reactionmedium is then concentrated to dryness under reduced pressure and theresidue (8.8 g) is taken up in 46.2 g of anhydrous DCE (total mass=55g).

Preparation of the Sample

2 drops of reaction medium are taken up with stirring and diluted with1.5 ml of MeOH+0.5 ml of CH₃CN.

Column: Xterra RP18 3.5 μm, 100 mm*4.6 mm. Mobile phase: A - 0.01MKH₂PO₄ buffer B - Acetonitrile Flow rate: 1.0 ml/min. Gradient: Time(min) % A % B  0 80 20 15 25 75 25 25 75 27 80 20 37 80 20 Detector: UVat 226 nm Injection: 10 μl of product in dioxane/H₂O (95/5) Retention:Product retention times 2.6 min p-methanesulfonamidophenol 3.4 minp-quinone monomethanesulfonimide 10.6 min dronedarone hydrochloride 11.3min 2-butyl-5-(methanesulfonamido)benzofuran-3-carbonyl chloride

Example 11 Synthesis of N,N-diethyl-N-(phenoxyethyl)amine hydrochloride(or N,N-diethyl-2-phenoxyethanamine)

A solution of 108.5 g (0.630 mol; 1.2 eq.) ofN-(2-chloroethyl)-N,N-diethylamine hydrochloride in 65 ml of water isadded slowly (over about 55 minutes) to a mixture containing 50 g (0.531mol) of phenol and 46.3 g (1.158 mol; 2.2 eq.) of NaOH in 270 ml ofwater. The mixture is stirred for 3 hours 30 minutes at 20° C. and thenfor 45 minutes at 55° C. The phases are separated by settling and thesupernatant oil diluted in 100 ml of DCE is washed with (i) 100 ml of2.5% sodium hydroxide and then (ii) with 100 ml of 5% sodium hydroxide.The product is dried over sodium sulfate and then concentrated. 81.4 gof crude N,N-diethyl-N-(phenoxyethyl)amine are obtained.

Mass yield: 79.3% by weight

¹H NMR (DMSO) δ 1.08 (t, 6H, 2-CH₃), 2.64 (q, 4H, 2-CH₂), 2.88 (t, 2H,CH₂-N), 4.05 (t, 2H, CH₂-O), 6.92 (m, 3 H, CH_(arom)), 7.27 (m, 2H,CH_(arom)); ¹³C NMR (DMSO) δ 12.0 (2-CH₃), 47.9 (2-CH₂-N), 51.8 (1-CH₂),66.5 (1-CH₂-O), 114.6, 120.7, 129.4 (5-CH_(arom)), 158.9 (1-C_(arom)-O).

N,N-Diethyl-N-(phenoxyethyl)amine hydrochloride is formed by dissolving35 g (0.181 mol) of the preceding N,N-diethyl-N-(phenoxyethyl)amine in450 ml of anhydrous MTBE, followed by sparging 7 g (0.181 mol) ofhydrogen chloride gas into the medium. The precipitate formed isisolated by filtration and dried in a ventilated oven at 55° C. for 3hours to give 40 g of N,N-diethyl-N-(phenoxyethyl)amine hydrochloride.

Example 12 Synthesis of N,N-dibutyl-N-(3-phenoxypropyl)aminehydrochloride (or dibutyl(3-phenoxypropyl)ammonium chloride)

The process is performed in the same manner as previously (Example 13),starting with 138 g (1.466 mol; 1.15 eq.) of phenol, 109.5 g (2.738 mol;2.15 eq.) of NaOH, 530 ml of distilled water and 308.9 g (1.275 mol; 1eq.) of N-(3-chloropropyl)-N,N-dibutylamine hydrochloride. The mixtureis refluxed for 16 hours. The oil formed is separated out by settlingand washed with 500 ml of water and then diluted with 500 ml of MTBE andwashed with 500 ml of 2%o HCl. The MTBE phase is concentrated undervacuum and the oil is dried by azeotropic distillation with DCM. 307.1 gof the crude derivative N,N-dibutyl-N-(3-phenoxypropyl)amine areobtained.

Mass yield: 91.4% by weight 297.3 g (1.13 mol) of theN,N-dibutyl-N-(3-phenoxypropyl)amine isolated previously are stirred in600 ml of DCE, and 148.9 g (1.469 mol; 1.3 eq.) of 36% HCl are added, at20° C. The mixture is stirred for 1 hour at this temperature and driedby azeotropic distillation with DCE until a water content ≦0.01% isobtained, and is then concentrated under vacuum. 363.1 g ofN,N-dibutyl-N-(3-phenoxypropyl)amine hydrochloride are obtained.

Titer: 93.7% (Yld 100%).

¹H NMR (DMSO) δ 0.93 (t, 6H, 2-CH₃), 1.36 (sextet, 4H, 2-CH₂), 1.77 (m,4H, 2-CH₂), 2.33 (m, 2H, CH₂), 2.98 (m, 4H, 2-CH₂-N), 3.19 (m, 2H,CH₂-N), 4.04 (t, 2H, CH₂-O), 6.82, 6.93, 7.24 (m, 5H, CH_(arom)); ¹³CNMR (DMSO) δ 13.6 (2-CH₃), 20.2 (2-CH₂), 23.8 (1-CH₂), 25.0 (2-CH₂),50.4 (1-CH₂-N), 52.5 (2-CH₂-N), 64.7 (1-CH₂-O), 114.4, 121.4, 129.6,(5-CH_(arom)), 158.1 (1-C_(arom)-O).

Example 13 Synthesis of dronedarone coupling by Friedel-Crafts reactionof 2-butyl-5-methanesulfonamidobenzofuran-3-carboxylic acid chloridewith N,N- dibutyl-N-(3-phenoxypropyl)amine hydrochloride

7.34 g (22.5 mmol) of N,N-dibutyl-N-(3-phenoxypropyl)amine hydrochlorideand 40 g of DCE are introduced into the total amount (55 g) of thepreceding reaction medium of Example 10. The mixture is cooled tobetween 0 and 5° C. and 12 g (4 eq.) of AlCl₃ are added. The reactionmedium is stirred at 20-25° C. for 4 hours and then hydrolyzed bypouring it into 75 ml of water at between 0 and 5° C. The organic phaseis washed twice with 75 ml of water, filtered and then washed again with75 ml of water and concentrated under reduced pressure. 6.8 g of crudeproduct are obtained.

The crude product is purified by dissolution in 50 ml of DCE and washedwith 40 ml of 10% sodium hydroxide and 50 ml of water, and finally thecrude product thus obtained is purified by chromatography on silica,eluting with ethyl acetate (90v)/methanol (10v). 2.2 g of dronedaroneare obtained in a purity of 94.6%.

Mass yield: 16.6% by weight

¹H NMR (DMSO) δ 0.83 (t, 3 H, CH₃), 0.85 (t, 6 H, 2-CH₃), 1.20 to 1.50(unresolved complex, 6H, 3-CH₂), 1.69 (m, 2H, CH₂), 1.90 (m, 2H, CH₂),2.40 (m, 4H, 2-CH₂-N), 2.57 (m, 2H, CH₂-N), 2.80 (t, 2H, CH₂), 2.87 (s,3H, CH₃-S), 4.06 (broad t, 2H, CH₂-O), 6.92 (d, 2H, CH_(arom))_(,) 7.25,7.34, 7.39 (m, 3H, CH_(arom)), 7.78 (d, 2H, CH_(arom)), 12.19 (s, 1H,NH); ¹³C NMR (DMSO) δ 13.7 (1-CH₃), 14.1 (2-CH₃), 20.7 (2-CH₂), 26.9,28.0 (2-CH₂), 30.0 (1-CH₂), 29.2 (2-CH₂), 38.9 (1-CH₃-S), 53.9(2-CH₂-N), 50.3 (1-CH₂-N), 66.6 (1-CH₂-O), 114.3, 131.7 (4-CH_(arom)),111.7, 115.6, 120.2 (3-CH_(arom)), 116.8, 128.1, 132.8 (3-C_(arom)),131.3 (1-C_(arom)-N), 151.8, 163.3, 165.7 (3-C_(arom)-O), 190.4 (1-CO).

Example 14 Synthesis of phenyl2-butyl-5-methanesulfonamidobenzofuran-3-carboxylate (or phenyl2-butyl-5-(methanesulfonamido)benzofuran-3-carboxylate)

The following solution is placed in a 250 ml reactor containing the acidchloride of Example 10 in solid residue form: 3.53 g of phenol (1.2 eq.)and 50 ml of CH₂Cl₂ (anhydrous). The medium dissolves gradually. Theaddition vessel is rinsed with 50 ml of CH₂Cl₂ (anhydrous).

The following solution is added to the reaction medium at 30-35° C.:2.47 g of pyridine (1 eq.), 25 ml of dichloromethane (anhydrous). Thereaction medium is extracted with a mixture of 6.3 g of HCl (36%) and100 ml of H₂O (distilled). The mixture is stirred for 15 minutes and thephases are then separated by settling. The organic phase is then washedwith: 50 ml of H₂O and 30 g of about 3% NaOH. The organic phase iswashed again with: 50 ml of H₂O and then concentrated, and the followingis added to precipitate the product: 100 ml of cyclohexane. The mixtureis concentrated under vacuum at 20-25° C. to gradually remove the DCM.The mixture is filtered. 14.4 g of oily residue to be purified areobtained. Calculated titer (if 100% yield taking into account theorganic purity obtained by HPLC)=84%

Same analytical method as for Example 10.

Example 15 Synthesis ofN-[2-butyl-3-(4-hydroxybenzoyObenzofuran-5-yl]methanesulfonamideaccording to a Fries reaction

4 g of phenyl 2-butyl-5-methanesulfonamidobenzofuran-3-carboxylate and40 ml of chlorobenzene are placed in a 100 ml four-necked flask. Themixture is stirred until dissolution is complete, and 4.1 g of AlCl₃ (4equivalents) are then added and the mixture is heated at 95° C. for 17hours. The reaction medium is cooled to 20-25° C. and diluted with: 40ml of CH₂Cl₂. The mixture obtained is hydrolyzed by pouring it into 80ml of H₂O, without exceeding 35° C. The resulting mixture is stirred at20-25° C. until the gums have disappeared, and the phases are thenseparated by settling. The organic phase is washed once again with 80 mlof H₂O. 50 ml of H₂O are added to the organic phase and the pH isadjusted to 12.5 by addition of: 2.3 g of NaOH (30%). The mixture isstirred at 20-25° C. and the phases are then separated by settling.

The aqueous phase is brought to acidic pH by addition of 1.6 g of HCl(36%), 40 ml of CH₂Cl₂ are added, the mixture is stirred and the phasesare then separated by settling.

After concentrating the organic phase, 2.3 g of solid residue areobtained and are purified by flash chromatography to give 1.09 g of thedesired intermediate (para isomer).

Mass yield=27.3%

Same analytical method as for Example 10.

1. A process for synthesizing a keto benzofuran derivative, in base form(i), or in the form of an addition salt with an acid (ii), said ketobenzofuran derivative being of formula (I) below:

in which G1 represents a linear or branched alkyl (i), haloalkyl (ii),cycloalkyl (iii), substituted or unsubstituted aryl (iv), alkene (v) oralkyne (vi) group, G3 represents (i) a group —NHSO₂Rc or (ii) a group—NHRc, in which Rc represents (a) a linear or branched alkyl group, (b)a cycloalkyl group or (c) a substituted or unsubstituted aryl group, G5represents a halogen atom or a group —ORb in which Rb represents ahydrogen atom, an alkyl, haloalkyl, aryl, arylalkyl, heteroaryl,cycloalkyl or heterocycloalkyl group or an -alkyleneaminoalkyl group, Rarepresents a substituent chosen from halogen atoms and alkyl, haloalkyl,alkoxy and alkoxyalkyl groups, na is an index equal to 0, 1, 2, 3 or 4,said process comprising a Friedel-Crafts acylation reaction, saidreaction taking place starting with an intermediate of formula (II)

in which the groups G1 and G3 are as defined above and in which thegroup G2 is chosen from halogen atoms, the —OH group, alkoxy and aryloxygroups and —NRdRe with Rd and Re being identical or different and beingchosen, independently of each other, from a hydrogen atom, alkyl groupsand aryl groups, said alkyl and aryl groups being optionallysubstituted.
 2. The process as claimed in claim 1, characterized-in-thatwherein said compound of formula (II) is prepared by dehydration of acompound of formula (IX):

in which G1 and G3 are as defined for the keto benzofuran of formula (I)as claimed in claim 1 and in which the group G2 is chosen from halogenatoms, the —OH group, alkoxy and aryloxy groups and —NRdRe with Rd andRe being identical or different and being chosen, independently of eachother, from a hydrogen atom, alkyl groups and aryl groups, said alkyland aryl groups being optionally substituted.
 3. The process as claimedin claim 2, wherein said compound of formula (IX) is prepared by acyclization reaction of a compound of formula (VIII):

in which G1, G2 and G3 are as defined in claim
 2. 4. The process asclaimed in claim 1, wherein the compound of formula (I) for which G3represents —NH-SO2-Rc and G5 represents ORb is prepared by nucleophilicsubstitution of a compound of formula RbX in which X is a halogen atomand Rb represents an alkyl, haloalkyl, aryl, arylalkyl, heteroaryl,cycloalkyl or heterocycloalkyl group or an -alkyleneaminoalkyl group ona compound of formula (12):

in which G1, Ra, Rc and na are as defined for the keto benzofuran (I) asclaimed in claim
 1. 5. A compound of formula (II), in base form, or inthe form of pharmaceutically acceptable addition salts with organic ormineral acids, said compound (II) having the following formula:

in which G1 is as defined for the keto benzofuran of formula (I) asclaimed in claim 1; G2 is chosen from halogen atoms, the —OH group,alkoxy and aryloxy groups and —NRdRe with Rd and Re being identical ordifferent and being chosen, independently of each other, from a hydrogenatom, alkyl groups and aryl groups, said alkyl and aryl groups beingoptionally substituted; G3 represents (i) a group —NHSO₂Rc or (ii) agroup —NHRc, in which Rc represents (a) a linear or branched alkyl groupor (b) a cycloalkyl group.
 6. A compound of formula (VIII), in baseform, or in the form of pharmaceutically acceptable addition salts withorganic or mineral acids, said compound (VIII) having the followingformula:

in which G1 is as defined for the keto benzofuran of formula (I) asclaimed in claim 1; G2 is chosen from halogen atoms, the —OH group,alkoxy and aryloxy groups and —NRdRe with Rd and Re being identical ordifferent and being chosen, independently of each other, from a hydrogenatom, alkyl groups and aryl groups, said alkyl and aryl groups beingoptionally substituted; G3 represents (i) a group —NHSO₂Rc or (ii) agroup —NHRc, in which Rc represents (a) a linear or branched alkylgroup, (b) a cycloalkyl group or (c) a substituted aryl group,
 7. Acompound of formula (IX), in base form, or in the form ofpharmaceutically acceptable addition salts with organic or mineralacids, said compound (IX) having the following formula:

in which G1 and G3 are as defined for the keto benzofuran of formula (I)as claimed in claim 1 and in which the group G2 is chosen from halogenatoms, the —OH group, alkoxy and aryloxy groups and —NRdRe with Rd andRe being identical or different and being chosen, independently of eachother, from a hydrogen atom, alkyl groups and aryl groups, said alkyland aryl groups being optionally substituted.
 8. A compound of formula(12), in base form, or in the form of pharmaceutically acceptableaddition salts with organic or mineral acids, said compound having thefollowing formula:

in which G1, Ra, Rb, Rc and na are as defined for the keto benzofuran(I) as claimed in claim 1, with the exclusion of the compoundN-[2-butyl-3-(4-hydroxybenzoyl)benzofuran-5-yl]methanesulfonamide. 9.The process according to claim 1, wherein said keto benzofuranderivative is dranedarone or the hydrochloride salt thereof.